The novel anthraquinone compound Kanglexin (KLX) has been investigated for its potential to prevent EndMT in atherosclerosis by targeting the fibroblast growth factor receptor 1 (FGFR1 ...

Figure 1: Structures of anthraquinone-containing enediynes and comparison of dynemicin A production by wild-type M. chersina and PKS gene deletion strains. Figure 2: Comparison of enediynes ...